Clinical trials: Seroprevalence
HIV Infections, HIV Seronegativity
HIV Prevention Preparedness Study
The purpose of this study is to provide researchers with information that will help them prepare for a future study to test the efficacy of two anti-HIV vaginal gels.
- Trial name
- NCT00048282
- Where
- 10 sites in South Africa, Tanzania and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Healthy Adult
Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program
This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students.
- Trial name
- NCT06901362
- Where
- Thailand
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Thammasat University
SARS-CoV-2 Seroprevalence
ANC COVID-19 Surveillance
The purpose of this observational study is to determine the seroprevalence of SARS-CoV-2 antibodies in the community with pregnant women aged 15-49 years attending first antenatal care as the sentinel population.
- Trial name
- NCT07021807
- Where
- Zambia
- Volunteers
- 9,111 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Sars-CoV2
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)
In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110).
- Trial name
- EpiCovCreil (NCT04404270)
- Testing
- Anti-SARS-CoV2 Serology, Questionnaire, Anti-SARS-CoV2 serological controls and serum neutralization
- Where
- France
- Volunteers
- 1,146 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Cholera
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol.
- Trial name
- NCT05829772
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Brucellosis, Low Back Pain
Seroprevalence of Brucella Antibodies in High-Risk Patients With Low Back Pain: A Case-Control Study
The goal of this observational case-control study is to assess the presence of Brucella antibodies in patients with low back pain who are at high risk for brucellosis exposure, such as those with animal contact or consumption of…
- Trial name
- NCT07112677
- Testing
- Brucella Antibody Testing (ELISA)
- Where
- 2 sites in Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Elham Ahmed Hassan
SARS-CoV Infection
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04880174
- Testing
- serological testing
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Hepatitis A, Viral Hepatitis Vaccines
Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico
This study will assess the seroprevalence of hepatitis A virus (HAV), hepatitis B virus (HBV) and Bordetella pertussis (B. pertussis) in adolescents and young adults in Mexico.
- Trial name
- NCT02112890
- Testing
- Data collection
- Where
- Mexico
- Volunteers
- 1,603 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2, COVID-19
COVID-19 Among Healthcare Workers in Belgian Hospitals
Due to the situation this study, originally planted until September 2020, was extended with 7 months until April 2021. This extension was approved by the ethical committee University hospital Ghent, Belgium.
- Trial name
- COVHECBEHO (NCT04373889)
- Where
- Belgium
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Sciensano
SARS-CoV Infection, Seroprevalence
COVID-19 Sero-prevalence Health Care Workers Kinshasa
This is a cohort study, in which the investigators will follow-up 650 health care workers (HCW) and a selection of their households (of COVID positive and COVID negative HCW) at baseline and in three follow-up surveys, with 4 to…
- Trial name
- PRESTACOV (NCT04699058)
- Testing
- COVID-antibody test
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Rickettsiae Infections
Rickettsiae in Myanmar
Rickettsial infections have been found to be the second most common cause of non-malarial febrile illness in Southeast Asia, just after dengue, and are largely neglected treatable causes of morbidity and mortality.
- Trial name
- Rickettsiae (NCT03847870)
- Testing
- MORU in-house ELISA test followed by IFA if positive
- Where
- Burma
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Myanmar Oxford Clinical Research Unit
Seroprevalence, Antibody
Population-based Age-stratified Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID-19) Infection in the Federation of Bosnia and Herzegovina
This study is the second cross-sectional study conducted in the region. In the first cross sectional study, conducted in the winter of 2020, we aimed to estimate the seroprevalence of SARS-CoV-2 IgG antibodies among blood donors…
- Conditions
- Seroprevalence, Antibody, COVID-19
- Trial name
- NCT05124535
- Where
- Bosnia and Herzegovina
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Institute for Public Health of the Federation of Bosnia and Herzegovina
Dengue, Dengue Fever
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01477671
- Where
- 4 sites in India
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company